Mounjaro is the diabetes-approved version of tirzepatide
This reflects the state of play as of early 2026: States that cover GLP-1s for obesity treatment (fee-for-service): Arkansas, Colorado, Connecticut, Delaware, Illinois, Louisiana, Massachusetts, Minnesota, New Mexico, New York, Oregon, Virginia, Washington approximately 13 states total as of January 2026
This documentation supports continuity of care, informs future prescribing decisions, and contributes to the broader understanding of Mounjaro's safety profile in real-world clinical practice
Not automatically
This code should be assigned as a secondary code after the manifestation code
GLP-1 medications should not be taken by people with a history of medullary thyroid cancer or multiple endocrine neoplasia syndrome type 2